pilepsy is a neurological disease that often requires longterm pharmacological treatment. Although monotherapy is the first option, satisfactory seizure control is not achieved in 30-40% of patients, making it necessary to use 2 or more antiepileptic drugs (AEDs) at the same time. 1, 2 Increasing the number of drugs used also increases the risk of undesirable interactions occurring, not only between the AEDs themselves, but also with any other drugs that patients may be taking.
In certain groups of patients, failure to anticipate potential interactions of AEDs with each other and with other drugs could lead to a major management problem, with the risk of adverse side effects and a loss of efficacy of the treatments used. Patients with refractory epilepsy and elderly people are sections of the population in whom polypharmacy is the norm. Elderly people in care homes typically take more than 5 drugs on a long-term basis and 5-10% receive some type of AED. 3, 4 The interaction of AEDs with contraceptives is an aspect that must be taken into consideration in young women. Other groups such as cancer patients, patients undergoing treatment with immunosuppressants and those who are HIV positive or have a psychiatric disorder, often take drugs that interact with AEDs. Moreover, antiepileptics are becoming increasingly widely used in other common conditions such as neuropathic pain and migraine.
Although newer AEDs have a better pharmacokinetic profile with a lower risk of interactions than older AEDs, they are not exempt from interactions and they are often used in combination with these older drugs. This article will review the main interactions that occur between AEDs and other commonly used drugs, as well as examining the guidelines for clinical management in groups of patients in whom these interactions are of particular importance.
GENERAL CONCEPTS REGARDING INTERACTIONS: TYPES OF INTERACTIONS
A drug interaction is defined as the modification of the effect of a drug caused by the action of another substance administered simultaneously. There can be 2 types of interactions between drugs: pharmacokinetic (when a drug alters the serum concentration of another) and pharmacodynamic (when a drug modifies the efficacy or toxicity of the other without changing its serum concentration). The serum concentration of a drug may be altered by any process that affects its absorption, distribution, metabolism or excretion. 5, 6 From a pharmacokinetic point of view, the ideal drug is one that presents a bioavailability of almost 100% with rapid absorption. It should have a low protein-binding capacity and a uniform distribution volume. Its elimination should be constant over time and proportional to the dose. It should preferably be eliminated through glomerular filtration by the kidneys rather than through the liver, because the latter is influenced by genetic factors and factors relating to diet, smoking, alcohol, age, state of health and concomitant medication, and therefore varies significantly from one individual to another. Furthermore, unlike renal clearance, there are no physiological markers for liver function that correlate with hepatic clearance. Therefore, the dose of drugs eliminated primarily through the kidneys may be more easily adjusted. Finally, the ideal drug should not form active metabolites and if it does, the initial drug should be an inactive form. A drug that includes all these characteristics will have a low potential for pharmacokinetic interactions with other substances (Table 1) . 5, 6 In practice, the most common and clinically important pharmacokinetic interactions are those that affect drug metabolism. Hepatic metabolism is the main route of elimination for most AEDs and many other drugs. Two types of reactions can be distinguished: phase I reactions (oxidation, reduction and hydrolysis); and phase II reactions (conjugation). Oxidative metabolism largely takes place thanks to the cytochrome P450 system, which consists of a family of some 100 isoenzymes, of which CYP 2C9, 2C19 and 3A4 are the most highly involved in AED oxidation. Many endogenous components such as steroid hormones, prostaglandins, vitamins and free fatty acids are also metabolized by this system. Glucuronic acid conjugation via uridine diphosphate glucuronyltransferase (UGT) is another major pathway in the metabolism of some AEDs, such as valproic acid and lamotrigine. Another system that should be taken into account is epoxide hydrolase, which acts on the active metabolite of carbamazepine (10,11-epoxy-CBZ) ( Table 2) . 7, 8 In general, any drug metabolized by the CYP or UGT systems may be affected by enzyme induction or inhibition by other drugs. Those with partial hepatic clearance will hardly be affected, unlike those with exclusive hepatic metabolism.
The genetic polymorphism of hepatic drug-metabolizing enzyme systems contributes to interindividual variability existing with some AEDs. Although most drugs are metabolized by the CYP 3A4 isoform, for which genetic polymorphisms have not been described, 0.1-2% of the population has a CYP 2C9 polymorphism, which makes them ultra-slow metabolizers of phenytoin, requiring doses 37% lower to achieve normal concentrations. This alteration has also been associated with slow phenobarbital metabolism. It is estimated that up to 2-4% of patients are ultra-slow metabolizers of diazepam and clobazam as a result of a CYP 2C19 polymorphism, with a possible effect on phenytoin and phenobarbital. Gilbert's syndrome involves a UGT deficiency that reduces the elimination of lamotrigine and valproic acid. 9, 10 It is important to bear in mind when combining inductive or inhibitory drugs that clinical consequences are not immediate. Although enzyme inhibition is a process that occurs immediately, its effects may be deferred by hours or several days until a stable concentration of the inhibitor drug and inhibited enzyme is reached. In the case of enzyme induction, this process may take longer, from days to weeks, as it includes not only the time it takes for induction to occur, but also the time needed to reach a stable concentration between the inducer drug and the induced enzyme. 11 Therefore, if a patient has a seizure after combining an enzyme inducer with another AED for several weeks, it may be caused by a decrease in the levels of the second drug resulting from enzyme induction, rather than a lack of efficacy of the AEDs.
The AEDs that most commonly cause interactions with each other and with other drugs are older AEDs: phenytoin, carbamazepine, phenobarbital, primidone and valproic acid. Their pharmacokinetic characteristics differ from those of the ideal drug, in that they have high protein-binding capacity, exclusively or predominantly hepatic metabolism, potent enzyme induction and inhibition, and active intermediate metabolites; this therefore makes them more difficult to manage in polytherapy. The newer AEDs are closer to the ideal model, although some of them, such as felbamate, oxcarbazepine, lamotrigine, topiramate and zonisamide, may modify or be modified by other AEDs (Table 3) .
Hepatic Enzyme-Inducing Antiepileptic Drugs
Most of the older AEDs, with the exception of valproic acid, are potent inducers of the major CYP isoenzymes. Phenytoin, carbamazepine, primidone and phenobarbital are broad-spectrum inducers of both the CYP system and UGT. 5, 11, 12 Clearance of carbamazepine, phenytoin, primidone, valproic acid, ethosuximide, clonazepam, clobazam, oxcarbazepine, topiramate, tiagabine, lamotrigine and zonisamide is therefore increased in the presence of any of these enzymeinducing AEDs. With valproic acid, carbamazepine, tiagabine and lamotrigine this effect is very pronounced and it may even be necessary to double the dose in order to reach serum concentrations similar to those achieved when administered alone. In treatments with valproic acid, it tends to be difficult to achieve levels above 75 mg/l when combined with enzyme inducers. In a study of patients taking carbamazepine and phenytoin in combination with lamotrigine, an improvement in seizure control was observed when older AEDs were withdrawn, as the concentrations of lamotrigine increased concurrently with an increase in its efficacy, and the enzyme-inducing action disappeared. 13 The effect of this enzyme induction may even make it necessary to alter the administration regimen of 
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AEDs. Many of the newer AEDs have a half-life of approximately 24 hours, which makes it possible to administer them once or twice a day. In the presence of an enzyme inducer, halflife is shortened and there may be significant fluctuations in serum levels, making it necessary to administer them 3 times a day. 5, 14 Obviously, when an enzyme-inducing AED is withdrawn in a patient receiving polytherapy, it is important to readjust the doses of the remaining drugs, as their levels will increase, with a consequent risk of side effects.
As well as being an enzyme-inducing drug, carbamazepine is affected by the autoinduction of CYP 3A4-mediated metabolism. This mainly occurs at the beginning of treatment, when clearance can increase up to 3 times during the first 2-3 weeks. Depending on the dose, in some cases this phenomenon may continue during the maintenance stage. 15 Another aspect to be taken into account is what happens when there is induction of an AED that has active metabolites. Combining carbamazepine with any CYP 3A4 inducer brings about a decrease in the concentration of carbamazepine but increases the concentration of its active metabolite, 10,11-epoxy-carbamazepine. It is therefore possible that combining a hepatic enzyme inducer with carbamazepine will cause undesirable side effects as the concentration of its active metabolite increases, even though plasma levels of carbamazepine are reduced. Another example is the induction of primidone metabolism by phenytoin, which brings about an increase in serum concentrations of phenobarbital. 16 Clobazam, a benzodiazepine commonly used in epilepsy, also has an active metabolite (N-demethylclobazam), the concentration of which increases with enzyme-inducing AEDs.
Among newer AEDs, felbamate and oxcarbazepine cause significant enzyme induction and topiramate is a mild CYP 3A4 inducer. Felbamate induces CYP 3A4 and reduces carbamazepine levels by 18-31%, while increasing its active metabolite by as much as 50% or more. 12 Being a mild CYP 3A4 inducer, topiramate does not have significant effects on other AEDs and its only important interaction is caused by a reduction in ethinyl estradiol concentrations, which could potentially influence the effect of contraceptives. Although it is a drug that may be significantly impacted by enzyme induction by carbamazepine and phenytoin, it is not affected by enzyme inhibition. 17 Compared with carbamazepine, oxcarbazepine is less capable of causing interactions. Its action on carbamazepine, phenytoin and valproic acid concentrations tends to result in moderate alterations in serum levels with few clinical implications. It can also act via UGT, reducing lamotrigine concentrations. 5 If a patient is taking carbamazepine in polytherapy and it is replaced by oxcarbazepine, it is important to consider the effect this will have on other AEDs when enzyme induction decreases, especially when taken in combination with phenytoin or valproic acid. Unlike carbamazepine, oxcarbazepine is not affected by autoinduction.
Rufinamide was recently introduced as an adjuvant drug in patients with Lennox-Gastaut syndrome. It is metabolized primarily by hydroxylation, with little involvement of the CYP system and no UGT involvement. In studies in animals, however, it has been observed that multiple doses of rufinamide induce CYP activity and the pharmacokinetics of AEDs, which are CYP 3A4 substrates. Simultaneous treatment with older enzyme-inducing AEDs (carbamazepine, phenytoin, primidone, phenobarbital) and vigabatrin, among newer AEDs, causes an increase in rufinamide clearance. 19 Significant decreases in phenytoin concentration of up to 20% have been recorded when combined with vigabatrin, generally after a few weeks. The mechanism by which this decrease occurs is unknown. Vigabatrin does not seem to affect the concentration of any other AED. 18, 20 Lamotrigine has a mild enzyme-inducing action on the UGT system, altering its own metabolism and undergoing a 25% decrease in its normal half life. 18 There are, however, contradictory results in this respect, as this phenomenon was not observed in a study carried out in epileptic children. 14 Similarly, the combination of lamotrigine and valproic acid also causes a 25% decrease in the plasma concentration of valproic acid. 12 Gabapentin, tiagabine, zonisamide, pregabalin and levetiracetam do not have an enzyme-inducing effect on other AEDs, although tiagabine and zonisamide are affected by enzyme induction. [21] [22] [23] Small variations have been observed in half-life and levels of levetiracetam in the presence of enzyme-inducing AEDs (decrease) and valproic acid (increase), although without any apparent clinical implications.
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Hepatic Enzyme-Inhibiting Antiepileptic Drugs
Valproic acid is the main enzyme-inhibiting AED. It acts on CYP 2C, UGT and epoxide hydrolase isoenzymes. It does not significantly affect CYP 3A4, so it would not be expected to have an effect on carbamazepine, but as it is an epoxide hydrolase inhibitor, it prevents the clearance of carbamazepine-active metabolite, increasing its levels and potentiating its effects. It is therefore possible to have symptoms of toxicity even with normal plasma levels of carbamazepine. Valproic acid slows down the elimination of phenobarbital, primidone and phenytoin. After adding valproic acid, phenobarbital concentrations increase over a period of several weeks, usually by 30-50%, and it can be necessary to reduce the dose of phenobarbital or primidone by up to 80%. 16 With phenytoin, not only is its metabolism inhibited, but there is also a displacement of phenytoin from its plasma proteinbinding sites, thereby making the interaction more complex and increasing the need to monitor both AEDs and measure the unbound fraction. 16 Valproic acid does not have any effect on the concentration of the monohydroxylated active metabolite of oxcarbazepine (10,11-dihydro-10-hydroxycarbamazepine). 18 Lamotrigine is an AED particularly sensitive to the inhibition that occurs when valproic acid is added, doubling its half-life and serum levels. This occurs with doses higher than 500 mg/day of valproic acid. As the risk of skin rash caused by lamotrigine depends on the rate at which its levels increase, lamotrigine should be introduced at lower doses and more slowly in patients on valproic acid, reaching total doses lower than those of patients not taking valproic acid. There does not seem to be a greater risk of skin rash with the introduction of valproic acid in a patient already on stable treatment with lamotrigine, but neurotoxic effects may be observed if the dose of lamotrigine is not reduced to half once the patient is taking 250-500 mg/day of valproic acid. 26 Among newer AEDs, felbamate, topiramate and oxcarbazepine cause CYP 2C19 inhibition, and they can alter the metabolism of drugs metabolized by this enzyme, predominantly phenytoin. 12 The CYP 2C19 isoenzyme plays a minor role in the metabolism of phenytoin but it becomes more important when the primary pathway, CYP 2C9, is saturated by high concentrations of phenytoin. Therefore, the interaction of topiramate with phenytoin is only important if there are high levels of phenytoin. 17 Both oxcarbazepine and its active metabolite have moderate enzyme-inhibiting effects on CYP 2C19. Clinical studies suggest that at doses of 1200 mg/ day of oxcarbazepine, the concentration of phenytoin may increase by up to 40% and the concentration of phenobarbital by 15%. 18 Zonisamide can also act as a mild inhibitor of CYP 2C19 and bring about a moderate increase in phenytoin levels. 27 Contradictory data have been published about whether or not zonisamide is able to inhibit carbamazepine metabolism. 12 Rufinamide can significantly reduce phenytoin clearance and it may be necessary to adjust the phenytoin dose. 19 Stiripentol is a drug with very limited use, although it may be useful in treating severe myoclonic epilepsy in childhood. It has the disadvantage of having multiple pharmacokinetic interactions. It is a potent inhibitor of phenytoin (dosedependent), carbamazepine, phenobarbital, valproic acid and clobazam, requiring a significant dose reduction of these drugs. Confusion and toxic symptoms have been described when stiripentol is taken with valproic acid. 28 Gabapentin, tiagabine, vigabatrin and levetiracetam do not seem to cause CYP, UGT or epoxide hydrolase inhibition and they are not affected by the inhibition induced by other AEDs. 12, 20, 22, 24, 25 Other Mechanisms of Pharmacokinetic Interaction Between Antiepileptic Drugs
Although the most common pharmacokinetic interactions are associated with the metabolism of AEDs, they can occur at any stage of the biotransformation of the drug. It has recently been noted that drugs that induce or inhibit CYP enzymes also alter the expression of transport proteins, including P-glycoprotein and multidrug resistance proteins (MRP2 and MRP3) in the gastrointestinal tract, kidney and other tissues. As a result, some of the interactions between AEDs that are thought to be associated with enzyme induction or inhibition may actually be mediated by a reduction in intestinal absorption or an increase in renal elimination. 16 It is possible that the increase in neurological toxicity of carbamazepine when combined with lamotrigine may be caused by lamotrigine inhibiting P-glycoprotein and facilitating carbamazepine access to the central nervous system. 29 In terms of distribution, AEDs that are highly plasma protein bound (phenytoin, valproic acid, and tiagabine) may compete for plasma proteins when they are administered simultaneously, thereby increasing the unbound fraction of the displaced AED, which is the effective fraction, but also the one responsible for side effects. This problem primarily occurs when phenytoin is displaced by valproic acid, in which case phenytoin may cause toxicity with normal total plasma levels. In this case, it is important to suspect this and measure the unbound fraction of phenytoin. 5 Interactions involving renal excretion are rare. Gabapentin, vigabatrin and levetiracetam are eliminated via this route, but no interactions between them have been reported. 12, 20, 25 Pharmacodynamic Interactions Between Antiepileptic Drugs
Simultaneous administration of drugs may increase their potency or toxicity without being associated with changes in their serum concentrations. Pharmacodynamic interactions are difficult to document, although clinical observations suggest that they are relatively common. A study that analyzed the frequency of adverse effects in a group of 767 epileptic patients over a 10-year period found that they occurred in 11.2% of patients and 80% of these effects were pharmacodynamic in nature. 30 It is important to bear in mind the main pharmacodynamic interactions between AEDs for 2 reasons: to look for combinations that potentiate the effect of each AED separately and to avoid multiplying adverse effects.
Examples of beneficial pharmacodynamic interactions between AEDs are the combination of valproic acid plus ethosuximide in absence epilepsy, valproic acid plus carbamazepine in partial seizures and valproic acid plus lamotrigine in generalised epilepsy. Although not well documented, there are other combinations that may also be beneficial.
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As far as the potentiation of adverse effects is concerned, it is clear that this will occur to a greater extent when AEDs with similar side effects are combined. This is often the case with neurotoxic effects such as sedation (combination of benzodiazepines and barbiturates) and ataxia (phenytoin plus carbamazepine, lamotrigine plus carbamazepine). The risk of exanthema and tremor is increased when valproic acid is combined with lamotrigine. Effects on weight may be additive (combination of valproic acid, gabapentin, pregabalin, carbamazepine) or antagonistic (topiramate with any of the aforementioned drugs). The risk of osteoporosis and idiosyncratic reactions involving the skin increase when enzyme-inducing AEDs are combined. A greater risk of encephalopathy caused by valproic acid has been described when this drug is combined with phenobarbital or topiramate. There is a greater theoretical risk of the formation of kidney stones when topiramate and zonisamide are combined, as they are both carbonic anhydrase inhibitors.
In terms of the teratogenic effects of AEDs, all the studies show that polytherapy increases the risk of malformations, one of the worst combinations being valproic acid and lamotrigine, for which the risk of malformations is above 12%.
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INTERACTIONS BETWEEN ANTIEPILEPTIC DRUGS AND OTHER DRUGS
As is the case between AEDs, the most frequent interactions occur with drugs that are metabolized in the liver, and (Tables 4 and 5) . 5 
Contraceptives
In 1979 Coulam and Annegers 33 compared 41 patients who were taking AEDs and oral contraceptives with another 41 patients with epilepsy only taking oral contraceptives. They observed more contraception failures in the group of patients taking both treatments combined. 33 The contraceptive failure rate was 6% per year, whereas it has been calculated that in women being treated with oral contraceptives alone and who take their treatment correctly, failures occur in less than 1% of cases. 34 The interaction involved in oral contraceptive failure in women with epilepsy is the induction of hepatic cytochrome P450, specifically the CYP 3A4 isoenzyme system. The induction of this system increases the metabolism of both estrogens and progestagens and may reduce the circulating levels of these hormones by up to 50%. 35, 36 This mainly occurs with enzyme-inducing AEDs such as phenobarbital, carbamazepine and phenytoin.
Among the newer AEDs, felbamate, topiramate and oxcarbazepine are weaker CYP 3A4 inducers. At low doses, felbamate may reduce the plasma level of progestagen by up to 42% without affecting estrogen levels. 37 Topiramate causes a significant reduction in ethinyl estradiol levels at doses above 200 mg, although the progestagen component hardly varies. 38, 39 Oxcarbazepine has been studied at doses of 1200 mg/day in healthy female volunteers taking oral contraceptives with 50 mg estradiol and 250 mg levonorgestrel and a 47% reduction in the area under the curve (AUC) was observed in both components. 40 It is therefore recommended that patients taking AEDs that induce the 3A4 system should use oral contraceptives containing at least 50 mg of ethinyl estradiol. If injections of depot medroxyprogesterone acetate are used, they should be administered at shorter intervals (10 weeks instead of the usual 12). Some authors recommend combining these injections with another method of contraception. 41 The case of lamotrigine and oral contraceptives is different. Ethinyl estradiol induces uridine diphosphate glucuronoyltransferase (UGT) 1A4, which reduces lamotrigine levels by up to 50%. This has important implications, because in the phase of the cycle when the oral contraceptive is being taken, the levels of lamotrigine decrease, with the consequent risk of seizures, and then during the phase of the cycle when the oral contraceptive is not being taken, lamotrigine levels
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can rise by up to 100% and have toxic effects. Slight reductions in progestagen have also been described (19% AUC and 12% of the maximum concentration) in combined treatments. 42 In patients who wish to continue with lamotrigine and oral contraceptives, it is possible to adjust the combined treatment time and reduce the dose of lamotrigine from the second day after stopping the oral contraceptives.
Non-enzyme-inducing AEDs such as valproate, gabapentin, levetiracetam, tiagabine, vigabatrin, zonisamide and pregabalin do not interact with oral contraceptives.
There is no evidence to suggest that oral contraceptives increase epileptic activity, and combined use with AEDs provides high pregnancy prevention rates that are not achieved by other alternative methods. 34 
Antimicrobials
Some macrolides are potent CYP 3A4 inhibitors and significantly increase the concentration of carbamazepine. 43 Clarithromycin and erythromycin are potent inhibitors of carbamazepine metabolism and they can increase its levels by up to 4 times, causing significant toxic effects. Should it be necessary to use a macrolide, azithromycin and spiramycin would be the most suitable. 26 Sulphonamides inhibit phenytoin metabolism and displace it from its protein binding sites. Their concurrent administration can lead to toxic effects. As carbapenem antibiotics inhibit the intestinal absorption of valproate and cause a significant reduction in its levels, it is not advisable to combine these drugs. 44 Phenobarbital increases the metabolism of chloramphenicol and can reduce its effectiveness, whereas phenytoin has the opposite effect. Chloramphenicol can increase the plasma levels of phenytoin and phenobarbital. 45 Enzyme-inducing AEDs accelerate the elimination of doxycycline and reduce its effectiveness. 46 Antifungal agents are potent P450 inhibitors. Ketoconazole and fluconazole thus cause a significant increase in carbamazepine levels, whereas miconazole and fluconazole cause an increase in phenytoin levels. Enzyme-inducing AEDs also reduce the concentrations of itraconazole by up to 10 times, and phenobarbital reduces the concentration and effectiveness of griseofulvin. 26 Neurocysticercosis is often associated with epilepsy and its effective treatment with antiparasitic agents (praziquantel and albendazole) may lead to interactions with AEDs. 47 Enzyme-inducing AEDs (phenytoin, phenobarbital and carbamazepine) cause an increase in the metabolism of praziquantel, which can lead to a 74-90% reduction in its plasma levels, as well as the inefficacy of the treatment. Likewise, they reduce albendazole levels, although slightly more moderately. 48 Enzyme-inducing AEDs may significantly reduce the levels of metronidazole, which in turn may increase the concentration of carbamazepine. 26 Although detailed studies are still required, interactions between AEDs and antiretroviral drugs are important from a clinical point of view. 49 Many antiviral agents (nevirapine, efavirenz, delavirdine, indinavir, ritonavir and saquinavir) are metabolized by CYP 3A4. Enzyme-inducing AEDs may reduce the concentrations of these drugs, making it necessary to increase the dose in order to achieve the desired clinical efficacy. It has been reported that the concentration of indinavir is up to 16 times lower when it is combined with carbamazepine. Valproate may inhibit the metabolism of zidovudine, thus increasing its levels and toxicity. 50 Ritonavir may increase the concentration of carbamazepine 2 or 3-fold. 26 There is controversy regarding the possible potential of valproate to increase viral replication in HIV, so its use is not usually recommended. 49 In these cases, gabapentin, lamotrigine and levetiracetam are the most indicated drugs.
Immunosuppressants
Pharmacological interactions of AEDs may cause complications in transplanted patients, as they may lead to clinically important effects with immunosuppressants. 51 Carbamazepine, oxcarbazepine, phenobarbital and phenytoin may reduce the levels of cyclosporin, tacrolimus and corticosteroids, delaying the immunosuppressant effect by up to 10 days. 52 Another problem that occurs in transplanted patients is drug-related seizures as a result of drug interactions in which AEDs are not involved. Drugs that increase the levels of cyclosporin (amlodipine, diltiazem, erythromycin, famotidine, ketoconazole, macrolides, metoclopramide, nicardipine and verapamil) have been associated with an increased risk of epileptic seizures. The concurrent administration of tacrolimus also reduces the metabolism of cyclosporin and increases its levels. Phenytoin has not proved to be very effective for these seizures and hemodialysis should be considered if seizures are refractory. 51 Levetiracetam is considered a valid alternative in these patients because of its pharmacokinetic profile, lack of drug interactions and the possibility of oral and intravenous administration.
Antineoplastics
To date, very little information has been published about the clinical consequences of interactions between AEDs and antineoplastics, and it has been based on isolated cases or series of cases in which a possible interaction has caused toxic effects or inefficacy. 53 Several pharmacokinetic studies have been published recently in which enzyme-inducing AEDs, such as phenytoin, phenobarbital and carbamazepine, reduce the levels of some antineoplastics, including cyclophosphamide, busulfan, paclitaxel, methotrexate and some vinca alkaloids, which means that increased doses are required if their efficacy is to be maintained. 53 With some antineoplastics that have active metabolites, such as cyclophosphamide, enzyme induction can stimulate the bioactivation process and increase the effects of the drug. 54 Many antineoplastic drugs can also affect the metabolism of AEDs. Fluorouracil, doxifluridine and tamoxifen have an inhibitory action on the metabolism of phenytoin and can cause phenytoin intoxication. Carmustine, alone or in combination with cisplatin and etoposide, has been associated with decreases of up to 50% in the concentration of phenytoin. A reduction in plasma levels of carbamazepine and valproate has also been described with cisplatin, and in levels of valproate alone with methotrexate. 26 Certain reductions in AED concentrations have been associated with problems in their intestinal absorption as a result of damage to the mucosa caused by antineoplastics.
Newer AEDs have a more favourable pharmacokinetic profile, with a smaller possibility of interactions occurring with other drugs and a lower risk of adverse drug reactions. Therefore, although there is little information about possible interactions with antineoplastics and their efficacy in epileptic seizures in cancer patients, the newer non-enzyme-inducing antiepileptics seem to be a better option than the older antiepileptics in cancer patients. 53 
Psychotropic Drugs
Pharmacokinetic and pharmacodynamic interactions between psychotropic drugs and AEDs are complex, and because psychiatric disorders also coexist in patients with epilepsy, they can often be a source of clinical problems.
Enzyme-inducing AEDs increase the metabolism of tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, chlorimipramine, doxepin), thus reducing their effect. Newer antidepressants (mianserin, nomifensine, bupropion, nefazodone, paroxetine and citalopram) also interact with enzyme-inducing AEDs, although more moderately. Valproate inhibits the metabolism of amitriptyline, nortriptyline, and to a lesser degree, paroxetine; it can therefore be associated with a 50-60% increase in the blood concentrations of the antidepressant, which may lead to toxic effects or a worsening of epileptic seizures as a result of the epileptogenic effect of these antidepressants. 26 Antidepressants can also affect the metabolism of AEDs. The concentration of phenytoin is increased when it is administered in combination with fluoxetine, fluvoxamine, sertraline, trazodone, viloxazine and imipramine, and the concentration of carbamazepine is increased by viloxazine, trazodone, nefazodone and fluoxetine. The concentration of valproate and lamotrigine can be increased by sertraline. 26 Enzyme-inducing AEDs also reduce the concentrations of almost all antipsychotics (haloperidol, chlorpromazine, clozapine, olanzapine, risperidone, quetiapine and ziprasidone). There may be a moderate increase in the concentration of haloperidol with topiramate. Risperidone may also cause a 20% increase in carbamazepine levels. 55 A 95% reduction in the concentrations of midazolam has been described when it is administered in combination with enzyme-inducing AEDs, which may cancel out its clinical effect.
Anticoagulant Drugs
Interactions between AEDs and oral anticoagulants pose an important clinical problem. With these drugs, which have a narrow therapeutic index, the presence of pharmacokinetic or pharmacodynamic interactions can cause significant complications. 16 There is clear evidence that enzymeinducing AEDs, especially phenobarbital and carbamazepine, stimulate the metabolism of warfarin and coumarin derivatives, reducing their clinical effect and requiring an increased dose of anticoagulants. 56 The dose is adjusted according to each individual, but up to 10 times the initial dose may be required, involving repeated international normalized ratio measurements. The greatest danger occurs when treatment with enzyme-inducing AEDs is stopped, thus delaying the metabolism of the anticoagulants, and if the dose is not reduced, severe hemorrhagic complications may occur. Valproate can increase serum concentrations of warfarin and can also lead to bleeding, interfering directly with platelet function and coagulation. 57 As interactions with phenytoin are more complex and unstable (the anticoagulation effect could either increase or decrease), concomitant use is not recommended. 16 Among newer AEDs, oxcarbazepine, levetiracetam and tiagabine have not been shown to interact with anticoagulants at normal doses, so their use is recommended when concomitant administration is necessary.
Ticlopidine has been associated with increases in plasma concentrations of phenytoin and carbamazepine, resulting in dose-dependent toxic effects. 58 
Cardiovascular Drugs
Interactions between enzyme-inducing AEDs and antihypertensive drugs, such as beta-blockers (propanolol, metoprolol) and calcium antagonists (nifedipine, felodipine, nimodipine, verapamil), are common. It is not recommended to administer these drugs in combination as dose adjustment tends to be difficult. 26 A reduction in the concentration of losartan has been described when combined with phenytoin, and also in the case of nimodipine with valproate.
Phenytoin reduces the concentration of digoxin, which usually requires dose adjusting. Topiramate can cause a slight reduction in the concentration of digoxin, but this is usually not of clinical importance. 12 Diltiazem increases the concentrations of phenytoin and carbamazepine and, in particular, verapamil acts as a potent inhibitor of carbamazepine metabolism, with the consequent possibility of clinical toxicity. 26 Lipid-lowering drugs (atorvastatin, lovastatin, simvastatin and fluvastatin) interact with enzyme-inducing AEDs, reducing their clinical efficacy. In contrast, valproate and felbamate, which have a hepatic enzyme-inhibiting action, increase the plasma concentrations of lipid-lowering drugs and may be responsible for clinical toxicity. 26 
Gastrointestinal Drugs
Antacids containing divalent cations, such as sucralfate, and enteral nutrition formulas administered via a nasogastric tube may alter the absorption of phenytoin, causing a reduction in its plasma concentration. 5 Cimetidine reduces the metabolism of phenytoin and carbamazepine, which may have clinical implications, especially in the case of phenytoin. Omeprazole increases the plasma concentrations of phenytoin by approximately 25% and, to a lesser extent, those of carbamazepine. Famotidine and pantoprazole do not have significant interactions with enzyme-inducing AEDs and would therefore be more indicated if concomitant use is necessary. 26 
Others
Phenobarbital, phenytoin and carbamazepine induce the metabolism of corticosteroids, reducing their clinical effectiveness, so that higher doses are required.
It has been reported that acetaminophen causes a 15% increase in the metabolism of lamotrigine, thus reducing its clinical effectiveness.
Other commonly used drugs in which a reduction in concentration has been described when combined with enzyme-inducing AEDs are theophylline, fentanyl, methadone, thyroxine, vecuronium and other neuromuscular blocking agents. 26 
CONCLUSION
There are several reasons why it is important to be familiar with the main pharmacokinetic characteristics of AEDs and their potential for interactions. First, they are drugs that are relatively widely used in the long-term treatment of prevalent conditions such as epilepsy, neuropathic pain and psychiatric diseases, often in polytherapy. Second, epileptic seizures occur during the progression of many diseases such as cerebrovascular disease, neoplasia, and infections such as HIV. Older AEDs are the primary source of pharmacokinetic interactions with each other and with other drugs. Carbamazepine, phenytoin and phenobarbital reduce the levels and effect of many AEDs and other substances, such as contraceptives with a low estrogen content, antiretroviral drugs, major immunosuppressants, widely used antineoplastic agents and oral anticoagulants. Valproic acid is a broadspectrum inhibitor and will have the opposite effect. If administered without adjusting the dose of other drugs that are being taken simultaneously, it can lead to toxicity problems or overdose (particularly important when combined with lamotrigine, some antineoplastics and anticoagulants). The interaction profile is generally much more favourable for most widely used newer AEDs. Drugs such as gabapentin, levetiracetam, pregabalin and vigabatrin will not cause important interactions and therefore (with the exception of vigabatrin) they are recommended for polytherapy in epileptic patients and particular groups such as patients with cancer, transplants, anticoagulant treatments or HIV infection. Lamotrigine has little potential for interactions except when combined with valproic acid (efficacy and side effects are mutually potentiated) and when administered with oral contraceptives, which can reduce lamotrigine levels by up to half. Oxcarbazepine and topiramate are AEDs with an average potential for interactions, usually with other AEDs and with contraceptives, according to the dose. Although many have been described, there are certain important pharmacokinetic interactions with AEDs that are caused by other commonly used drugs. These include potent carbamazepine inhibition, often leading to toxicity, which is caused by certain macrolides, ritonavir, antifungals (which also affect phenytoin) and verapamil. Another example is the blocking of the intestinal absorption of valproic acid caused by carbapenem antibiotics. Complex 2-way interactions have also been described between certain antineoplastics and phenytoin, as well as a reduction in the efficacy of the older enzyme-inducing AEDs by certain lipid-lowering drugs.
